KLF2 and hematoma: In this optimized model, we found the combined treatment effectively increased the expression of KLF-2 and ZO-1, attenuated the expression of NF-kB, which improved the inflammatory reaction, stabilized the neovascularization, and rapidly decreased the hematoma volume, resulting in the lowest mortality when comparing to other treatment groups.